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NATIONAL INSTITUTES OF HEALTH LUNG FUNCTION SCORE AS A POTEN-
TIAL MARKER FOR THE DEVELOPMENT OF CHRONIC GRAFT-VERSUS-
HOST DISEASE
Walter, E.C.1,2, Vigorito, A.1, Campregher, P.V.1, Martin, P.1,
Flowers, M.1, Chien, J.W.1,2 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Washington School of Medicine, Seattle, WA
Background: The NIH has recommended lung function be mon-
itored using a lung function score (LFS) to diagnose and monitor
chronic graft-versus-host disease (GVHD) of the lung following he-
matopoietic cell transplantation (HCT). However, the relationship
between posttransplant lung function and GVHD has not been
rigorously analyzed.
Methods: We performed a retrospective analysis of 1650 patients
who underwent allogeneic HCT from January 1992 to December
2004 and received pulmonary function testing (PFT) within
60–120 days after transplant (day 80 PFT). The primary exposure
was lung function score and primary outcome a diagnosis of chronic
GVHD in the year following day 80 PFT. Post transplant FEV1,
FVC, TLC, and DLCO were categorized as $ 80, 70–79, 60–69,
and\ 60% predicted. Lung function score (range 2–12) was calcu-
lated using FEV1 and DLCO and then categorized (1–3) according
to NIH recommendations. Chronic GVHD was diagnosed accord-
ing to current NIH guidelines. Cox proportional hazards were calcu-
lated to assess for the relationship between lung function and the
development of chronic GVHD.
Results: There was a stepwise increase in risk of developing
chronic GVHD with each categorical increase in LFS. The risk
of developing chronic GVHD was 1.5 and nearly 3-fold higher
for patients in the LFS categories representing the most severe
lung function [LFS category 2 hazard ratio (HR), 1.46 (95% CI
1.10–1.95); category 3 HR 2.75 (1.00–7.59)]. A similar effect
was seen for FEV1, FVC, and DLCO but not TLC. After adjust-
ment, risk estimates remained largely unchanged. Models using
individual PFT parameters performed similar to models using
LFS categories as judged by c-statistic calculations. At one year
following PFT, there was no difference in the proportion of pa-
tients diagnosed with chronic GVHD depending on LFS cate-
gories. However, the time to a diagnosis of chronic GVHD was
shorter for those patients with the most severe lung function (me-
dian days until diagnosis, 34 for LFS category 3 vs. 126 for LFS
category 0).
Summary: Poor lung function 80 days post allogeneic HCT is
associated with an increased risk of developing chronic GVHD
within the year following PFT. When assessing posttransplant
lung function, FEV1 alone appears to perform as well as the
LFS. These data suggest that routine PFTs following transplant
may help identify patients at higher risk for chronic GVHD and
may allow for earlier interventions to prevent or decrease post-
transplant complications.
Association between lung function score and the subsequent
development of chronic GVHD
LFS category Chronic GVHD (%) Unadjusted HR (95% CI) p-value0 270 (42) Referent -
1 269 (42) 1.07 (0.91-1.27) 0.425
2 59 (45) 1.46 (1.10-1.95) 0.009
3 5 (45) 2.75 (1.00-7.59) 0.050Definition of abbreviations: HR5 hazard ratio; CI5 confidence interval.
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IN VIVO MODULATION OF T CELL AND MONOCYTE FUNCTION FOLLOW-
ING INFUSION OF MESENCHYMAL STROMAL CELLS (MSC)
Castilla-LLorente, C.1,2, Mielcarek, M.1, Iwata, M.1, Abrams, V.K.1,
Hwang, B.1, Nash, R.A.1, Torok-Storb, B.1 1Fred Hutchinson Cancer Re-
search Center, Seattle, WA; 2Hospital Morales Meseguer, Murcia, Spain
Mesenchymal stromal cells (MSCs) expanded ex vivo from aspi-
rated marrow, have been used clinically with variable success. While
it is now generally acknowledged that these benefits are not the result
of engraftment and differentiation of MSC into the target tissues, themechanism by which these beneficial effects are achieved is not clear.
We hypothesize that MSCs mediate their effect by activating an en-
dogenous cell population which in turn modulates the immune re-
sponse and/or homes to damaged tissue and participates in repair.
To test this hypothesis immortalized and cloned populations of ca-
nine MSC were generated to provide a consistent product for in
vivo testing. We evaluate one line, DS-1, by infusion into two normal
dogs. Blood samples were taken pre and immediately post infusion
and at 1, 6, 24, 48, 72, 96 hours, and weekly till day 28. Following
infusion there was no consistent change in the number of WBC,
however by day 3 there was a marked decrease in the % of CD31
cells expressing FOXP3 and TGFb in the blood, which did not re-
cover to pre-infusion levels during the period of observation. At au-
topsy there was an increased number of these cells in the lymph
nodes and spleen, whereas there was an overall decrease in the num-
ber of TH1 cells in these tissues. Quantitative RT- PCR analysis of
cDNA prepared from blood mononuclear cells indicated an upregu-
lation in the expression of CD133, Tie-2, and MARCO between 1–
24 hours post infusion, and an increase in LOX1/OLR1 between 2–4
days. However the % of monocytes and the expression levels of
CD14, CD68, CD45, and CD105/Endoglin were constant at all
time points. Samples taken post infusion were also analyzed for the
presence of DS-1 cells by PCR and in vitro out growth assays.
Results indicated that the DS-1cells were detectable up to 6 hours
post infusion, but not thereafter. Adherent cells grown from blood
mononuclear cells at days 4 and 7, displayed macrophage and endo-
thelial cell morphologies. RT-PCR analysis of these cultures de-
tected expression of macrophage associated markers CD141/
CD681/MARCO1/LOX11, and endothelial cell associated
markers CD341/CD144/VECAD1. These data indicate that a sin-
gle infusion of DS-1 cells results in activation of circulating mono-
cytes and a shift of regulatory T cells from the periphery to lymph
nodes and spleen which persists for at least 28 days. We speculate
that these changes may contribute to the immunomodulatory effects
reported for some preparations of MSC.35
CO-TRANSPLANTATION OF CORD BLOOD WITH WHARTON’S JELLY
DERIVED UMBILICAL CORD – MESENCHYMAL STEM CELL S (UC-MSC)
IMPROVES SHORT TERM MYELOID ENGRAFTMENT INTO NOD/SCID/IL-
2RGNULL MICE
Paganessi, L.A., Walker, A.L., Fung, H.C., Christopherson, K.W. Rush
University Medical Center, Chicago, IL
Hematopoietic stem cells (HSC) are routinely obtained from bone
marrow, mobilized peripheral blood, and umbilical cord blood (CB).
Adult bone marrow has been traditionally utilized as the preferred
source of mesenchymal stem cells (MSC) to provide the stromal com-
ponent necessary to fulfill the requirement of the stem cell niche,
thereby preserving the microenvironment for HSC function. Bone
marrow-derived MSC (BM-MSC) have been shown to maintain the
growth of CB HSC ex vivo and promote engraftment into immunode-
ficient mice. However, the use of a BM-MSC as a feeder layer to sup-
port ex vivo culture and/or hematopoietic stem cell transplantation
(HSCT) of CB may not be the most ideal scenario for the clinical
transplant setting. Recently, MSC obtained from the Wharton’s Jelly
of the umbilical cord (UC-MSC) were shown to have mesenchymal
stem and/or progenitor cell potential as well as secrete several impor-
tant cytokines and growth factors. Having shown in our lab that UC-
MSC exhibit important functional characteristics of stromal cells,
such as the ability to support the maintenance of CB CD341 cells in
long term culture-initiating cell (LTC-IC) assays, we further hypoth-
esized that UC-MSC are able to promote engraftment of CB. To test
this hypothesis, we evaluated the effect of UC-MSC co-transplanta-
tion in the Non-Obese Diabetic/Severe Combined Immunodeficient
/IL-2 Receptor gnull (NOD/SCID/IL2Rgnull) mouse model of
HSCT. We report here that co-transplantation of CB with UC-
MSC resulted in an increase in the percentage of short term repopulat-
ing cells in the bone marrow of sub-lethally irradiated mice three
weeks post transplant. Specifically, increases in the percentage of
CD451 cells from 5.061.0% to 7.860.8% and from 1.160.5% to
11.161.7% were noted for CD341 and MNC recipient mice respec-
tively. In addition, statistically significant increases in the percentage
of CD341, CD341CD38-, CD341CD381, CD331, CD611, and
16 Oral PresentationsCD141 cells were also noted in both CD341 and MNC recipient mice
(p# 0.05, n5 3). No significant change in CD191 cells was noted in
any treatment group. This data suggests that UC-MSC have the abil-
ity to enhance short term myeloid reconstitution. It may therefore be
possible to develop UC-MSC methodologies to both improve ex vivo
CB culture and increase transplant efficiency. Additionally, it may be
preferred that CB HSC and MSC be genetically identical or from an
HLA-matched or unmatched non-adult MSC tissue source.36
IMPROVED ENGRAFTMENT IN AN NOD-SCID IL-2RGNULL MOUSE MODEL
FOLLOWING TRANSPLANTATION OF FUCOSYLATED CORD BLOOD
MONONUCLEAR CELLS
Robinson, S.N.1, Yang, H.1, Decker, W.K.1, Xing, D.1, Steiner, D.1,
Simmons, P.J.2, Miller, L.3, Cooper, L.J.N.4, de Lima, M.J.1,
Champlin, R.E.1, Shpall, E.J.1, Zweidler-McKay, P.A.4 1University of
Texas M.D. Anderson Cancer Center, Houston, TX; 2University of Texas
Health Science Center at Houston, Houston, TX; 3America Stem Cell,
Inc., Carlsbad, CA; 4University of Texas M.D. Anderson Cancer Center,
Houston, TX
Cord blood (CB) provides a readily available, ethnically-diverse
source of hematopoietic tissue for transplantation, however, low
cell dose delays engraftment and increases risk of graft failure. In ad-
dition, it has also been suggested that CB hematopoietic stem cells
(HSC) home less efficiently to the hematopoietic microenvironment
after transplantation when compared to bone marrow or peripheral
blood HSC. Homing mechanisms may rely, at least in part, on the
interaction between fucosylated glycoproteins on the surface of
HSC and P- and E-selectins expressed by the microvasculature of
the hematopoietic system. Glycoproteins expressed on the surface
of CB HSC appear to be poorly fucosylated. It has been proposed
that the use of a fucosyltransferase (FT) to increase levels of surface
glycoprotein fucosylation may improve homing to the bone marrow
and thereby improve engraftment. In an initial series of experiments,
levels of fucosylation of surface glycoproteins expressed on CB
CD341 cells were increased using FT-VI (Engraftin, America
Stem Cell). When subsequently injected into an NOD-SCID IL-
2Rgnull mouse model, the rate and magnitude of human engraftment
was greater than in mice receiving a similar dose of untreated CB
CD341 cells. Since CB recipients receive mononuclear cells
(MNC) rather than selected CD341 cells, the efficacy of a fucosyla-
tion strategy using CB MNC was investigated.
Methods: MNC were obtained from a frozen CB unit. Half was
untreated and half fucosylated: incubation for 30 minutes at room
temperature with 1 mM GDP b-Fucose, 1 mM MnCl2 and FT-
VI. Fucosylated and untreated MNC were washed and each trans-
planted into sublethally-irradiated (270 cGy) NOD-SCID
IL-2Rgnull mice (5 mice/gp). Mice each received 6  106 CB
MNC (containing 2.5 104 CD341 cells) by tail vein injection. En-
graftment was followed at weekly intervals by flow cytometric mea-
surement of human CD451 cells in the peripheral blood.
Results: 6 weeks after transplantation, recipients of fucosylated
MNC showed a maximal 14% human engraftment, as compared to
1% in recipients of untreated MNC.
Conclusion: Consistent with preliminary data following trans-
plantation of fucosylated, or untreated CB CD341 cells, fucosylation
of CB MNC appears to improve both the rate and magnitude of en-
graftment. The efficacy of this technology will be explored in both
the single and double CB transplant settings and a clinical trial eval-
uating this approach will be designed and executed.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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PRE-ENGRAFTMENT SYNDROME (PES): A CLINICAL SYNDROME AFTER
CORD BLOOD (CB) TRANSPLANTATION NOT ASSOCIATED WITH ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) OR TRANSPLANT-RELATED
MORTALITY (TRM)
Patel, K.J., Rice, R.D., Hawke, R.M., Abboud, M., Heller, G.,
Scaradavou, A., Barker, J.N. Memorial Sloan-Kettering Cancer Center,
New York, NYPre-Engraftment Syndrome after cord blood transplantation
(CBT) is poorly characterized. Therefore, we conducted a review
of 52 double unit CBT recipients treated for high-risk hematological
malignancies to determine the incidence, manifestations, and
outcomes of PES. PES was defined as unexplained fever .38.3oC
(101oF) unresponsive to antibiotics and/or unexplained skin rash re-
sembling aGVHD occurring prior to or at neutrophil recovery. CBT
recipients [median 38 years (range 3–66)] received either ablative (n
5 36) or non-myeloablative (NMA, n5 16) conditioning and CSA/
MMF. The cumulative incidence (CI) of sustained donor engraft-
ment was 94% (95%CI:88–100) with neutrophil recovery at a median
of 25 days in ablative and 11 days in NMA recipients. The CI of day
100 grade II-IV aGVHD and day 180 TRM were 40% (95%CI:
27–53) and 24% (95%CI:13–35), respectively. Sixteen (31%) pa-
tients fulfilled PES criteria: 15 with fever [median 39oC/102.2oF
(range 38.4–39.4oC) at onset] at a median of 9 days (range 5–12)
with 13 of these also having rash, and 1 having rash alone. The re-
maining 36 ‘‘no PES’’ patients included 5 without fever or rash, 26
with fever due to infection, and 5 with fever thought to be due to in-
fection and possible PES. Sixteen received IV methylprednisolone
(MP) treatment [14 PES, 2 with infection and possible PES; median
dose 1 mg/kg (range 0.5–2), median duration 3 days (range 2–44)].
Of 16 MP treated patients, 15 had fever resolution in #24 hours
and 1 in\48 hours. Two non-treated patients included 1 with spon-
taneous resolution of rash and 1 who remained febrile for 33 days.
While 3 patients had recurrent fever attributed to PES after MP ces-
sation this resolved with brief re-treatment. There was no association
between patient demographics, conditioning, or graft characteristics
and development of PES. There was also no association between
PES and neutrophil recovery, graft failure, aGVHD, or day 180
TRM.
Association between PES and Transplant Outcome
Median Grade 2-4
Total
(N 5 52)
Day Neutrophil
Recovery
Graft
FailureaGVHD
d 1 100 TRM d 1 100PES n516
(31%)Ablative
(n512):
23 days
(range 14-33);
NMA
(n54): 22 days
(range 7-36)n52 n55; 50 days
(range 34-70)n54No PES
n536
(69%)Ablative: 25 days
(range 13-43);
NMA: 11
days (range 7-22)n52 n514; 41 days
(range 29-99)n54p 5 0.75 p 5 0.67 p 5 0.79 p 5 0.22Eleven (69%) PES patients developed hypoxia6 pulmonary infil-
trates at a median of 12 days (range 7–15) as compared to 16 (44%)
non-PES patients (p 5 0.138). In summary, PES is common after
CBT, precedes neutrophil engraftment, is distinct from and does
not predict for aGVHD, and responds promptly to short course ste-
roids. Patients should not be diagnosed with early aGVHD or
treated with extended courses of steroids. Further investigation of
the etiology of PES and the toxicity (especially pulmonary
manifestations) is indicated.38
CORD BLOOD (CB) EXTENDS TRANSPLANT ACCESS TO RACIAL AND ETH-
NIC MINORITIES: A PROSPECTIVE STUDY OF 309 UNRELATED SEARCHES
IN PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES
Lee, S.S., Scaradavou, A., Hawke, R.M., Webb, K.A., Wells, D.S.,
Abboud, M., Papadopoulos, E.B., Kernan, N.A., Barker, J.N. Memorial
Sloan-Kettering Cancer Center, New York, NY
HLA-A,B,C,DRB1 allele match improves unrelated donor (URD)
hematopoietic stem cell (HSC) transplant outcome but limits the
number of suitable donors. In contrast, CB transplantation (CBT)
is associated with a reduced HLA-match requirement. Therefore,
we prospectively evaluated donor availability in 309 patients [median
